Login to Your Account


Iron wrinkle: CRL delays Amag’s taking on ‘slow-start’ Injectafer

By Randy Osborne
Staff Writer

Wednesday, January 22, 2014
The delayed PDUFA date and lack of labeling talks with the FDA presaged unhappy news for Amag Pharmaceuticals Inc. regarding its supplemental new drug application (sNDA) for intravenous Feraheme (ferumoxytol), and a complete response letter (CRL) came next.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription